Y-mAbs Therapeutics (YMAB) Expected to Announce Quarterly Earnings on Monday

Key Points

• Y-mAbs Therapeutics is anticipated to release its Q2 2025 earnings on August 11th, with analysts estimating a loss of ($0.27) per share and revenue of $18.40 million.
• The company recently reported a negative net margin of 31.84% and a return on equity of -30.59%, with expectations of posting $-1 EPS for both the current and next fiscal years.
• Y-mAbs Therapeutics has received mixed ratings from analysts, with an average target price of $15.60 and several recent downgrades, alongside heavy institutional ownership of 70.85%.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $18.40 million for the quarter. Y-mAbs Therapeutics has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.10. The firm had revenue of $20.90 million during the quarter, compared to analysts' expectations of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 31.84% and a negative return on equity of 30.59%. On average, analysts expect Y-mAbs Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB opened at $4.44 on Monday. The stock has a market cap of $201.06 million, a P/E ratio of -6.94 and a beta of 0.57. The firm has a 50 day moving average price of $4.64 and a 200 day moving average price of $4.88. Y-mAbs Therapeutics has a 52-week low of $3.55 and a 52-week high of $16.11.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Oppenheimer cut their price target on shares of Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating on the stock in a research note on Thursday, May 29th. Truist Financial cut their price objective on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Bank of America lowered shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a research report on Tuesday, April 22nd. HC Wainwright dropped their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Finally, Wedbush reaffirmed an "outperform" rating and set a $18.00 price target (down from $21.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday, May 28th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $15.60.

Institutional Investors Weigh In On Y-mAbs Therapeutics

An institutional investor recently raised its position in Y-mAbs Therapeutics stock. AQR Capital Management LLC raised its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 869.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 164,788 shares of the company's stock after purchasing an additional 147,788 shares during the quarter. AQR Capital Management LLC owned 0.36% of Y-mAbs Therapeutics worth $730,000 as of its most recent SEC filing. 70.85% of the stock is currently owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.